Prestige Consumer Healthcare reported a 22.7% revenue increase to $336.3 million in Q2 fiscal 2027, driven by acquisitions of Breathe Right® and LaCorium. Adjusted diluted EPS rose to $1.13 from $1.07 last year, despite a decline in Clear Eyes® sales and supply challenges. The company lowered its full-year revenue guidance to $1.28-$1.29 billion and adjusted EPS to $4.48-$4.55, citing production issues at its Pillar5 facility. Management remains confident in long-term growth, supported by recent acquisitions and ongoing investments in production capacity.
Prestige Consumer Healthcare's fiscal 2027 Q2 results provide context for consumer staples investors. For readers following this sector, here is Pluang's market snapshot as of Nov 05, 2026 18:11 WIB: Among 63 priced US Consumer Staples stocks, 48 rose and 12 fell today. Notable movers include FIZZ (National Beverage Corp.) at USD 36.07 with a 1-day change of -4.20% and 100% sell order activity, AGRO (Adecoagro SA) at USD 8.77 with -3.72% and 100% buy order activity, and JBS (JBS N.V. Class A Common Shares) at USD 13.33 with +2.85% and 100% buy order activity.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
